-
Carcinosarcoma of the uterus is a rare condition accounting for less that 4% of all uterine neoplasms. Previous work has identified that the most active single agents are platinum, ifosfamide, paclitaxel, and doxorubicin.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
I love this article. It's relevant to our daily practice, but, more importantly, it verbalizes the same issues that both physicians and patients want clarified.
-
-
Add Natazia, an estradiol valerate/dienogest pill, to the list of oral contraceptives approved by the Food and Drug Administration (FDA) and now available to U.S. women.
-
National medical organizations have issued positions on adolescent care will impact your practice. Add the following to the next clinical discussion at your facility:
-
As of September 2010, federal health reform legislation will require all new private health plans to provide coverage of a slate of preventive health services at no cost to patients. Will contraception be included in that coverage? Reproductive health advocates are calling for such measures.
-
When it comes to unplanned pregnancy and sexually transmitted diseases (STDs), young women, adolescents, and the poor often are the most at risk. However, women from all socioeconomic groups face challenges to their sexual and reproductive health.
